# Pharvaris N.V. (PHVS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $35.25, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Pharvaris N.V. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 7.0×**. The shares trade at 7.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.3%** (5-yr avg -11.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -64.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -19.8%**. Earnings per share fell 19.8%.

## Dividends
- **Dividend: none**. Pharvaris N.V. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Pharvaris N.V.; the consensus is strong_buy, with an average price target of $49.28 (+40% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 60.4%** (YTD 27.0%, 3-mo 13.4%). The shares are up 60.4% over twelve months including dividends.
- **From 52-week high: -7.6%** (70.7% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.89** (volatility 55%). Beta of 0.89 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PHVS · Page: https://foliofundamentals.com/stocks/phvs

Not investment advice.